Restenosis in Intervened Coronaries with Hyperhomocysteinemia (RICH)

American Heart Journal

Volumn 146, Issue 6, 2003, Pages 1077-1081

  Kojoglanian, Samuel A ^a   Jorgensen, Michael B ^a,b   Wolde Tsadik, Girma ^a   Burchette, Raoul J ^a   Aharonian, Vicken J ^a  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

^b Kaiser Permanente Med Care Program ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE;

ADULT; AGED; ANGINA PECTORIS; ANGIOGRAPHY; ARTICLE; CORONARY ARTERY DISEASE; CORONARY STENT; FEMALE; FOLLOW UP; HUMAN; HYPERHOMOCYSTEINEMIA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESTENOSIS; SENSITIVITY ANALYSIS;

EID: 0345490826     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(03)00518-0     Document Type: Article

References (29)

1. Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001;345:1593-1600.
2. Schnyder G, Roffi M, Flammer Y, et al. Association of plasma homocysteine with restenosis after percutaneous coronary angioplasty. Eur Heart J 2002;23:726-33.
3. Kosokabe T, Okumura K, Sone T, et al. Relation of a common methylenetetrahydrofolate reductase mutation and plasma homocysteine with intimal hyperplasia after coronary stenting. Circulation 2001;103:2048-54.
4. Morita H, Kurihara H, Kuwaki T, et al. Homocysteine as a risk factor for restenosis after coronary angioplasty. Thromb Haemost 2000;84:27-31.
5. Kumbasar D, Dincer I, Ertas F, et al. Hyperhomocysteinemia and restenosis. J Cardiovasc Risk 2001;8:9-13.
6. Genser D, Prachar H, Hauer R, et al. Relation of homocysteine, vitamin B12, and folate to coronary in-stent restenosis. Am J Cardiol 2002;89:495-9.
7. Miner S, Hegele R, Sparkes J, et al. Homocysteine, lipoprotein (a), and restenosis after percutaneous transluminal coronary angioplasty: a prospective study. Am Heart J 2000;140:272-8.
8. Benoit C, Furber A, Le Bouil A, et al. Le dosage plasmatique de l'homocysteine n'est pas un facteur predictif de restenose apres angioplastie coronaire. Arch Mal Coeur Vaiss 1999;92:1457-60.
9. Bourassa M, Lesperance J, Eastwood C, et al. Clinical, physiologic, anatomic and procedural factors predictive of restenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1991;18:368-76.
10. Yokoi H, Nobuyoshi H, Nosaka H, et al. Coronary stenting for long lesions (lesion length >20 mm) in native coronary arteries: comparison of three different types of stent. Circulation 1996;94:1685.
11. Azer A, Detre K, Goldberg S, et al. A meta analysis of the clinical and angiographic outcomes of stents vs. PTCA in different coronary vessel sizes in the BENESTENT-1 and STRESS1, 2 trials. Circulation 1995;92:147.
12. Disciascio G, Vetrovec G, Cowley M, et al. Early and late outcome of percutaneous transluminal coronary angioplasty for subacute and chronic total coronary occlusion. Am Heart J 1986;111:833-9.
13. Topol E, Ellis S, Fishman J, et al. Multicenter study of percutaneous transluminal angioplasty for right coronary artery ostial stenosis. J Am Coll Cardiol 1987;9:1214-8.
14. Hirshfield J, Schwartz J, Jugo R, et al. Restenosis after coronary angioplasty: a multivariate statistical model to relate lesion and procedure variables to restenosis. J Am Coll Cardiol 1991;18:647-56.
15. Van Belle E, Bauters C, Hubert E, et al. Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native vessels. Circulation 1997;96:1454-60.
16. McCully K. Vascular pathology of homocysteine: implications for the pathogenesis of atherosclerosis. Am J Pathol 1969;56:111-28.
17. Kang S, Wong P, Malinow M, et al. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Ann Rev Nutr 1992;12: 259-68.
18. Bellamy M, McDowell I. Putative mechanisms for vascular damage by homocysteine. J Inherit Metab Dis 1996;20:307-15.
19. Starkbaum G, Harlan L. Endothelial cell injury due to copper catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986;77:1370-6.
20. Dudman N, Hicks C, Lynch J, et al. Homocysteine thiolactone disposal by human arterial endothelial cells and serum in vitro. Arterioscler Thromb 1991;11:663-70.
21. Harker L, Slichter S, Scott C, et al. Homocysteinemia: vascular injury and arterial thrombosis. N Engl J Med 1974;291:537-43.
22. Harker L, Harlen J, Ross R, et al. Effect of sulfinpyrazone on homocysteine induced endothelial injury and atherosclerosis in baboons. Circ Res 1983;53:731-9.
23. Tsai J, Perrella M, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A 1994;91:6369-73.
24. Van Aken B, Jansen J, Reisma P, et al. Homocysteine increases IL-6 production by human monocytic cell line monomac-6. J Vasc Res 1996;33:103.
25. Rensing B, Hermans W, Vos J, et al. Luminal narrowing after percutaneous transluminal coronary angioplasty: a study of clinical, procedural and lesional factors related to long term angiographic outcome. Circulation 1993;88:975-85.
26. Bauthers C, Hubert E, Prat A, et al. Predictors of restenosis after coronary stent implantation. J Am Coll Cardiol 1996;31:1291-8.
27. Kereiakes D, Linnemeier T, Baim D, et al. Usefulness of stent length in predicting in stent restenosis (the multi-link stent trial). Am J Cardiol 2000;86:336-41.
28. Selhub J, Jacques PF, Wilson PW, et al. Vitamins status and intake as primary determinants of homocystinemia in an elderly population. JAMA 1993;270:2726-7.
29. Hernandez R, Macaya C, Iniquez A, et al. Midterm outcome of patients with asymptomatic restenosis after coronary balloon angioplasty. J Am Coll Cardiol 1992;92:1402-9.